Eslam Maher
LightNews LightNews
eslammaher.bsky.social
Eslam Maher
@eslammaher.bsky.social
43 followers 140 following 86 posts
Oncology trials and biostatistics https://scholar.google.co.uk/citations?user=ZbSK3WwAAAAJ
Posts Replies Media Videos
eslammaher.bsky.social
Nature retracts paper for data manipulation by Ph.D. student retractionwatch.com/2026/01/14/n...
Nature retracts paper for data manipulation by Ph.D. student
Nature has retracted a paper after an investigation at a U.K. institution found the first author — then a doctoral student — manipulated data.  The paper, which looked at the sensitivity of lu…
retractionwatch.com
January 15, 2026 at 6:04 PM
Reposted by Eslam Maher
jonathan-bartlett.bsky.social
'How to interpret hazard ratios', with @dominicmagirr.bsky.social and @timpmorris.bsky.social thestatsgeek.com/2026/01/15/h...
How to interpret hazard ratios
Survival analysis of time-to-event outcomes is very commonly performed using Cox’s famous proportional hazards model. The model estimates hazard ratios for the ‘effects’ of covari…
thestatsgeek.com
January 15, 2026 at 10:52 AM
eslammaher.bsky.social
Covariate adjustment in trials with survival endpoints using RobinCar2 www.rconis.com/blog/robinca...
RobinCar2: Reliable Covariate Adjustment Package – RCONIS
Research Consulting and Innovative Solutions.
www.rconis.com
January 15, 2026 at 10:31 AM
eslammaher.bsky.social
Comments on FDA's draft guidance on the use of Bayesian methodology in trials: www.linkedin.com/pulse/reflec...
Reflections on the FDA Draft Guidance (Jan 2026): Understanding Bayesian Operating Characteristics and Inferential Roles
Sharing some personal reflections after carefully reading the FDA’s January 2026 draft guidance on Bayesian methodology in clinical trials, particularly the discussion on operating characteristics. Wh...
www.linkedin.com
January 15, 2026 at 10:07 AM
eslammaher.bsky.social
The 100 most influential CEOs in oncology (2025) oncodaily.com/100/100-most...
The 100 Most Influential CEOs in Oncology in 2025 (Full List) - OncoDaily
The 100 Most Influential CEOs in Oncology in 2025 (Full List) / 100 Most Influential CEOs, Adam Garone, Albert Bourla, Alessandro Jacques Cortese, Alicia
oncodaily.com
January 10, 2026 at 12:03 PM
eslammaher.bsky.social
New US FDA Draft Guidance: Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
www.fda.gov/regulatory-i...
Use of Bayesian Methodology in Clinical Trials of Drug and Biological
This draft guidance provides guidance to sponsors and applicants on the appropriate use of Bayesian methods in clinical trials.
www.fda.gov
January 9, 2026 at 5:48 PM
eslammaher.bsky.social
ISBS Webinar: Is Repeated Bayesian Interim Analysis Consequence-Free? Speaker: Ying Yuan, to discuss his work with FDA here: arxiv.org/abs/2508.07403
us06web.zoom.us/meeting/regi...

30 Jan, 4 PM London
Welcome! You are invited to join a meeting: ISBS Webinar - Is Repeated Bayesian Interim Analysis Consequence-Free?. After registering, you will receive a confirmation email about joining the meeting.
Dear Fellow Statisticians, We are pleased to announce an exciting upcoming seminar as part of the ISBS Webinar Series on clinical trial innovation. The seminar, titled " Is Repeated Bayesian Interim A...
us06web.zoom.us
January 8, 2026 at 12:15 PM
eslammaher.bsky.social
New book! Estimands in Clinical Trials: A Practical Guide (Springer) link.springer.com/book/10.1007...
Estimands in Clinical Trials
This book gives guidance on implementing the estimand framework in diverse trial settings and explores real-world case studies.
link.springer.com
January 7, 2026 at 3:58 PM
eslammaher.bsky.social
Webinar: Philip He (Early phase statistics, Daiichi Sankyo) will talk about: Ensuring Quality and Interpretability of PFS and OS in Oncology Clinical Trials

🗓 Date & Time: Friday, Jan 16th, 2026
08:00 – 09:00 AM (PDT)

Zoom link in this post:
www.linkedin.com/posts/yi-pan...
#dahshu #idswg #kolseminar #oncologyclinicaltrials #clinicaltrialdesign #progressionfreesurvival #overallsurvival #estimands #iche9r1 #oncologystatistics #biostatistics #regulatoryscience… | Yi Pan
✨ Jan 2026 DahShu IDSWG KOL Seminar ✨ We are honored to welcome Dr. Philip He as our distinguished speaker! 📘 Title: Ensuring Quality and Interpretability of Progression Free Survival and Overall ...
www.linkedin.com
December 30, 2025 at 1:34 PM
Reposted by Eslam Maher
pgmj.bsky.social
"40 percent of MRI signals do not correspond to actual brain activity"; "Since tens of thousands of fMRI studies worldwide are based on this assumption, our results could lead to opposite interpretations in many of them.”
www.tum.de/en/news-and-...
40 percent of MRI signals misinterpreted
Interpretation of numerous MRI data may be incorrect: blood flow is not a reliable indicator of brain activity.
www.tum.de
December 28, 2025 at 8:40 AM
eslammaher.bsky.social
UK ECMC network's 99 gene panel recommendations
www.nature.com/articles/s41...
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology - British Journal of Cancer
British Journal of Cancer - Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology
www.nature.com
December 28, 2025 at 1:05 PM
eslammaher.bsky.social
Eleven clinical trials that will shape medicine in 2026 rdcu.be/eWeT4
Eleven clinical trials that will shape medicine in 2026
Nature Medicine - Nature Medicine asks leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and...
rdcu.be
December 24, 2025 at 8:58 PM
eslammaher.bsky.social
Robust Modestly Weighted Log-Rank Tests
onlinelibrary.wiley.com/doi/10.1002/...
Robust Modestly Weighted Log‐Rank Tests
The introduction of checkpoint inhibitors in immuno-oncology has raised questions about the suitability of the log-rank test as the default primary analysis method in confirmatory studies, particular...
onlinelibrary.wiley.com
December 18, 2025 at 2:27 PM
eslammaher.bsky.social
Authors here estimate of DOR with IPCW, using JAVELIN Renal-101 trial data, and inference with resampling methods. This would account for competing/intercurrent events. They also provide code here: lmaowisc.github.io/dor/
evidence.nejm.org/doi/10.1056/...
Evaluating Treatment Effects with Patient-Response–Related Outcomes in Comparative Clinical Trials
In comparative clinical investigations for nearly all disease types, patient responses — signifying clinically meaningful improvements in health or reductions in disease burden — are routinely empl...
evidence.nejm.org
December 18, 2025 at 2:22 PM
eslammaher.bsky.social
Why are 3+3 phase 1 designs still being used? Frustrating
December 16, 2025 at 10:39 AM
Reposted by Eslam Maher
benvancalster.bsky.social
Our guidance regarding performance measures for medical AI models is finally out!

- Stop bashing AUROC, although it does not settle things
- Calibration and clinical utility are key
- Show risk distributions
- Classification statistics (e.g. F1) are improper

www.thelancet.com/journals/lan...
Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance
Numerous measures have been proposed to illustrate the performance of predictive artificial intelligence (AI) models. Selecting appropriate performance measures is essential for predictive AI models i...
www.thelancet.com
December 13, 2025 at 2:04 PM
eslammaher.bsky.social
Comments on ICH E20 draft guidance from all the leading UK experts on adaptive trial methodology! Here www.regulations.gov/comment/FDA-... and www.regulations.gov/comment/FDA-...
Regulations.gov
www.regulations.gov
December 10, 2025 at 11:38 AM
eslammaher.bsky.social
Update in R: "x %notin% table newly in base is an idiom for !(x %in% table) and provided almost entirely for convenience and code readability..."
stat.ethz.ch/R-manual/R-d...
R: R News
stat.ethz.ch
December 10, 2025 at 5:27 AM
Reposted by Eslam Maher
sim0ngates.bsky.social
More on single arm trials (stop me if you think you've heard this one before). I'd actually really like someone to argue against what I'm saying here. There are loads of trials like this one, which seems problematic.

simonelgato.github.io/2025/12/06/n...
Single arm neuroblastoma trial
This post is about this trial: Furman et al. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clin Cancer Res (2019...
simonelgato.github.io
December 6, 2025 at 3:56 PM
eslammaher.bsky.social
TiTE-STEIN www.tandfonline.com/doi/full/10....
TITE-STEIN: Time-to-event simple toxicity and efficacy interval design to accelerate phase I/II trials
Oncology dose-finding trials are shifting from identifying the maximum-tolerated dose (MTD) to determining the optimal biological dose (OBD), driven by the need for efficient methods that consider ...
www.tandfonline.com
December 6, 2025 at 10:22 PM
eslammaher.bsky.social
Version 2.0 of crmPack
www.rconis.com/blog/crmPack...
crmPack 2.0: A Major Milestone for Adaptive Dose Escalation Trials – RCONIS
Research Consulting and Innovative Solutions.
www.rconis.com
December 6, 2025 at 12:09 PM
Reposted by Eslam Maher
brennankahan.bsky.social
New paper in @jclinepi.bsky.social: **Estimands: what they are and why we should use them**

We provide simple explanations of:
-estimands and intercurrent events
-how these relate to familliar concepts like ITT
-how to write estimands for protocols
-and more

www.jclinepi.com/article/S089...
Estimands: what they are and why we should use them
In clinical trials, postrandomization events, such as treatment discontinuation or the use of rescue medication, can complicate the interpretation of results. An estimand is a precise description of t...
www.jclinepi.com
December 5, 2025 at 1:29 PM
Reposted by Eslam Maher
vickersbiostats.bsky.social
For those who complained about the recent RCT on PSA not looking at overall mortality, note that Gil Welch, the well-respected screening skeptic, concluded "It is not feasible to test all-cause mortality when screening for an individual cancer"
pubmed.ncbi.nlm.nih.gov/37639251/
Testing Whether Cancer Screening Saves Lives: Implications for Randomized Clinical Trials of Multicancer Screening - PubMed
It is not feasible to test all-cause mortality when screening for an individual cancer. However, it is feasible to test all-cause mortality for multicancer screening because cancer deaths are such a large component of deaths in general. Observational data on the effects of cancer screening are misle …
pubmed.ncbi.nlm.nih.gov
December 4, 2025 at 4:19 PM
eslammaher.bsky.social
Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers jamanetwork.com/journals/jam...
Randomized Clinical Trials for Children With Poor-Prognosis Cancers
This special communication reports multistakeholder consensus recommendations regarding randomized clinical trials of new therapies for children with poor-prognosis cancers.
jamanetwork.com
December 5, 2025 at 10:41 AM
Reposted by Eslam Maher
jdwilko.bsky.social
Why does every target trial emulation study have to include a bit that says "this shows how great target trial emulation is. RCTs are non-generalisable and expensive"? Imagine if every RCT said "this shows how great RCTs are. We did not have to rely on strong, untestable assumptions".
November 27, 2025 at 12:05 PM